GPVI Antibody | 4771

GPVI Antibody | 4771 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: GPVI antibody was raised against a 18 amino acid synthetic peptide near the center of the human GPVI.
The immunogen is located within amino acids 130 - 180 of GPVI.

Research Area: Homeostasis

Tested Application: E, WB

Application: GPVI antibody can be used for detection of GPVI by Western blot at 1 μg/mL.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1205 – Jurkat Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 37, 68 kDa
Observed: 55 kDa 

Validation: N/A

Isoform: N/A

Purification: GPVI Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: GPVI Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: GPVI antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: GPVI Antibody: GPIV, GPVI, BDPLT11, Platelet glycoprotein VI, Glycoprotein 6

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: GPVI Antibody: Glycoprotein VI (GP6) is a 58kD platelet membrane glycoprotein that plays a crucial role in the collagen-induced activation and aggregation of platelets. It is uniquely expressed by cells of the megakaryocytic/platelet lineage, and is a member of the immunoglobulin gene superfamily, closely related to Fc receptor gamma chain (FcRgamma) and natural killer receptors. Glycoprotein VI plays a key role in platelet procoagulant activity and subsequent thrombin and fibrin formation. This procoagulant function may contribute to arterial and venous thrombus formation. The signaling pathway involves the FcRgamma, the Src kinases (likely Fyn/Lyn) , the adapter protein LAT and leads to the activation of phospholipase C gamma2. GPVI deficiency can result in bleeding disorders. Further study should reveal the extent of GPVI involvement in thrombotic disease and allow the development of alternative anti-thrombotic compounds.